Notable regulatory and funding developments shape the biotech landscape. The reinstatement of the U.S. childhood vaccine safety task force aims to enhance vaccine monitoring amid controversial leadership. Biopharma deal activity surged with unprecedented financial volumes despite fewer total deals in 2025. Kriya Therapeutics secured a $313 million funding round to advance gene therapies. Additional regulatory approvals and clinical trial updates from companies including Beam, Everest, and Sanofi were reported, highlighting ongoing momentum in drug development and oversight.